Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
07:25am, Tuesday, 12'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTCT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PTC Therapeutics, Inc. Shareholders Who Lost Money
07:25am, Monday, 11'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
10:48pm, Thursday, 29'th Feb 2024
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
07:01pm, Thursday, 29'th Feb 2024
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metri
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
06:21pm, Thursday, 29'th Feb 2024
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $0.29. This compares to loss of $2.35 per share a year ago.
PTC Therapeutics to Participate at Upcoming Investor Conferences
05:20pm, Tuesday, 27'th Feb 2024
SOUTH PLAINFIELD, N.J. , Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44t
PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing
04:23pm, Thursday, 25'th Jan 2024
The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the co
PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript
06:11am, Sunday, 29'th Oct 2023
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Execu
Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?
08:33am, Friday, 27'th Oct 2023
PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
09:03pm, Thursday, 26'th Oct 2023
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall St
PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 26'th Oct 2023
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.
Why PTC Therapeutics Soared 15% Higher Today
07:02pm, Thursday, 19'th Oct 2023
The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma.
PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion
09:18am, Thursday, 19'th Oct 2023
PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monetize up to $1.5 billion of the royalty stream for t
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
04:30pm, Monday, 16'th Oct 2023
SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 finan
PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?
09:47am, Wednesday, 11'th Oct 2023
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre
